MSH2 and neoplasm: Tumor testing corroborated the sequencing results: IHC of the proband’s tumor showed loss of EpCAM, MSH2, and MSH6 with retention of MLH1 and PMS2, consistent with MSH2-pathway deficiency; MSI testing demonstrated 30.43% unstable loci (MSI-H).